<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bibby JA</submitter><funding>Intramural Research Programs of the National Human Genome Research Institute</funding><funding>Innovative Medicines Initiative</funding><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>RCUK | Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>3412</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7343868</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>Regulatory B cells restrict immune and inflammatory responses across a number of contexts. This capacity is mediated primarily through the production of IL-10. Here we demonstrate that the induction of a regulatory program in human B cells is dependent on a metabolic priming event driven by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) is required to specifically drive IL-10 production, and to attenuate Th1 responses. Furthermore, GGPP-dependent protein modifications control signaling through PI3Kδ-AKT-GSK3, which in turn promote BLIMP1-dependent IL-10 production. Inherited gene mutations in cholesterol metabolism result in a severe autoinflammatory syndrome termed mevalonate kinase deficiency (MKD). Consistent with our findings, B cell</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate.</pubmed_title><pmcid>PMC7343868</pmcid><funding_grant_id>206618/Z/17/Z</funding_grant_id><funding_grant_id>777357</funding_grant_id><funding_grant_id>115142-2</funding_grant_id><funding_grant_id>MR/M012328/2</funding_grant_id><pubmed_authors>Rosenzweig S</pubmed_authors><pubmed_authors>Perucha E</pubmed_authors><pubmed_authors>Bibby JA</pubmed_authors><pubmed_authors>Okkenhaug K</pubmed_authors><pubmed_authors>Chandra A</pubmed_authors><pubmed_authors>Hayday T</pubmed_authors><pubmed_authors>Kemper C</pubmed_authors><pubmed_authors>Cope AP</pubmed_authors><pubmed_authors>Purvis HA</pubmed_authors><pubmed_authors>Lachmann HJ</pubmed_authors><pubmed_authors>Aksentijevich I</pubmed_authors><pubmed_authors>Wood M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate.</name><description>Regulatory B cells restrict immune and inflammatory responses across a number of contexts. This capacity is mediated primarily through the production of IL-10. Here we demonstrate that the induction of a regulatory program in human B cells is dependent on a metabolic priming event driven by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) is required to specifically drive IL-10 production, and to attenuate Th1 responses. Furthermore, GGPP-dependent protein modifications control signaling through PI3Kδ-AKT-GSK3, which in turn promote BLIMP1-dependent IL-10 production. Inherited gene mutations in cholesterol metabolism result in a severe autoinflammatory syndrome termed mevalonate kinase deficiency (MKD). Consistent with our findings, B cell</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-22T19:34:37.595Z</modification><creation>2025-04-06T02:47:32.855Z</creation></dates><accession>S-EPMC7343868</accession><cross_references><pubmed>32641742</pubmed><doi>10.1038/s41467-020-17179-4</doi></cross_references></HashMap>